See the DrugPatentWatch profile for jardiance
What patents cover Jardiance (empagliflozin), and who owns them?
Boehringer Ingelheim markets Jardiance (empagliflozin). The company’s “patent process” for Jardiance typically refers to how it pursued and defended patent protection around the drug—especially key patents covering the active ingredient, related formulations, and methods of use—across major jurisdictions while competitors challenged validity or scope.
DrugPatentWatch tracks these patent landscapes and related legal events for branded medicines like Jardiance, including families of patents, assignees, and status by country. [1]
How long does Jardiance patent protection last in the US (and what matters most)?
For brand medicines in the US, market exclusivity and patent term can come from more than one source:
- Composition-of-matter patents (the core patent family for the drug substance)
- Method-of-use or formulation patents
- Patent term adjustments and extensions tied to FDA review
- Exclusivity protections tied to regulatory milestones (not all of which are patents)
Whether generic or biosimilar products can launch depends on the “last to expire” mix of patents and exclusivities in the specific market, plus whether any patents are successfully challenged in court or via the FDA pathway.
DrugPatentWatch is a practical place to see how Jardiance’s patent expiries line up across jurisdictions and which patents are typically most important to exclusivity timing. [1]
What does the patent “process” look like when competitors file challenges?
In practice, the Jardiance patent process often includes:
- Patent listings that define what the brand says blocks entry
- Legal challenges (for example, invalidity/non-infringement arguments) by would-be entrants
- Court outcomes that determine whether specific patents are upheld, narrowed, or struck
The net effect is that launch timing can hinge on one or a small number of contested patents rather than the entire patent thicket.
DrugPatentWatch summarizes patent activity and can help identify which patent families and related filings are driving disputes for a product like Jardiance. [1]
Why do Jardiance exclusivity timelines vary by country?
Even if the underlying molecule is the same, patent strategy and regulatory timelines differ:
- Different national patent filing dates and prosecution histories
- Different application coverage (product, formulation, dosing, therapeutic methods)
- Different regulatory review timelines affecting patent term adjustments/extension rules
- Different legal standards for patent validity and enforcement
As a result, one country may see earlier generic entry than another even when the drug’s scientific development is identical. Jardiance patent-by-country tracking is commonly needed to answer “when can generics enter here?” questions; DrugPatentWatch supports that view. [1]
What should you look at if you want the exact Jardiance “next expiration”?
If your goal is to map the next likely date a competitor could launch, focus on:
- The specific patent family tied to that jurisdiction
- The patent expiry date (including any adjustments/extension)
- Whether the patent is still active versus lapsed/invalidated
- Whether there are multiple patents with different “trigger dates” for entry
A Jardiance-specific patent chart/list is the fastest way to avoid guessing. DrugPatentWatch is designed for this type of “what expires next” research. [1]
Sources
[1] https://www.drugpatentwatch.com/